A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment

Health Technology Assessment

Volumn 11, Issue 13, 2007, Pages

  Wilson, J ^a   Yao, G L ^a   Raftery, J ^a   Bohlius, J ^b   Brunskill, S ^c   Sandercock, J ^a   Bayliss, S ^a   Moss, P ^a   Stanworth, S ^c   Hyde, C ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF COLOGNE   (Germany)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ANOREXIA; ASTHENIA; BACKACHE; BLEEDING; CANCER; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COCHRANE LIBRARY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COUGHING; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; DYSPEPSIA; DYSPNEA; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED MEDICINE; FATALITY; FATIGUE; FEVER; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HERPES ZOSTER; HUMAN; HYPERTENSION; INJECTION PAIN; LIMB PAIN; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PRURITUS; PURE RED CELL ANEMIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SIDE EFFECT; SKIN IRRITATION; SURVIVAL RATE; SYSTEMATIC REVIEW; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

EID: 34250677127     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta11130     Document Type: Review

References (171)

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91:1616-34.
2. Mercante S, Gebbia V, Marrazzo A, Filosto S. Anemia in cancer: pathophysiology and treatment. Cancer Treat Rev 2000; 26:303-11.
3. Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol 2001;28(2 Suppl 8):7-14.
4. British Committee for Standards in Haematology BTTF. Guideline for the clinical use of red blood cell transfusions. Br J Haematol 2001; 113:24-31.
5. Weisen AR, Hospenthal DR, Byrd JC, Glass KL, Howard RS, Diehl LF. Equilibration of haemoglobin concentration after transfusion in medical patients not actively bleeding. Ann Intern Med 1994; 121:278-80.
6. Anon. The transfusion of red cells. In Mollison PL, Engelfriet CP, Contreras M, editors. Blood transfusion in clinical medicine, 10th ed. Oxford: Blackwell Science; 1997. Chapter 9, pp. 278-87.
7. Swisher SN, Petz LD. Transfusion therapy for chronic anemic states. In Petz LD, Swisher SN, Kleinman S, Spence RK, Strauss RG, editors. Clinical practice of transfusion medicine. New York: Churchill Livingstone; 1996. pp. 458-9.
8. McClelland DB. Handbook of transfusion medicine. London: The Stationery Office; 2001.
9. Hill SR, Carless PA, Henry DA, Carson JL, Hebert PC, McClelland DB, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2002;(2):CD002042.
10. Hoffbrand AV, Pettit JE, Moss P. Essential haematology. 4th ed. Malden, MA: Blackwell Science; 2001.
11. Kleinman S, Chan P, Robillard P. Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev 2003; 17(2): 120-62.
12. Stainsby D, Jones H, Milkins C, Gibson B, Norfolk DR, Revill J, et al. Serious Hazards of Transfusion Annual Report 2003. Manchester: SHOT Office; 2003. URL: www.shot-uk.org. Accessed 11 August 2004.
13. McClelland DB, Contreras M. Appropriateness and safety of blood transfusion. BMJ 2005; 330:104-5.
14. Amin M, Fergusson D, Aziz A, Wilson K, Coyle D, Herbert P. The cost of allogeneic red blood cells - a systematic review. Transfus Med 2003;13:275-85.
15. Varney SJ, Guest JF. The annual cost of blood transfusions in the UK. Transfus Med 2003; 13:205-18.
16. National Blood Service. Blood matters. Report No. 15. London:-National Blood Services; 2004.
17. Roberts DJ. Blood substitutes. In Murphy MF, Pamphilion DH, editors. Practical transfusion medicine. Oxford: Blackwell Science; 2001. pp. 279-86.
18. Henry DA, Carless PA, Moxey AJ, O'Connell D, Forgie MA, Wells PS, et al. Pre-operative autologous donation for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2001;(4).
19. Carless PA, Henry DA, Anthony DM. Fibrin sealant use for minimising peri-operative allogeneic blood transfusion. Cochrane Database Syst Rev 2003;(1).
20. Carless PA, Henry DA, Moxey AJ, O'Connell D, Fergusson D. Cell salvage for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2003;(4).
21. Henry DA, Moxey AJ, Carless PA, O'Connell D, McClelland DB, Henderson KM, et al. Antifibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 1999;(4).
22. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Deceased erythropoietin response in patients with anaemia of cancer. N Engl Med 1990;322:1689-92.
23. Harrison L, Shasha D, Shiova L, White C, Ramdeen B, Porenoy R. Prevalence of anaemia in cancer patients undergoing radiation therapy. Semin Oncol 2001;28(Suppl 8):54-9.
24. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. 47th ed. London: Royal Pharmaceutical Society; 2004.
25. Lind M, Vernon C, Cruickshank D, Wilkinson P, Littlewood T, Stuart N, et al. The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. Br J Cancer 2002; 86:1243-9.
26. Holzner B, Kemmler G, Greil R, Kopp M, Zeimet A, Raderer M, et al. The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Ann Oncol 2002;13:965-73.
27. Bottomley A, Thomas R, Van Steen K, Flechtner H, Djulbegovic B. Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about? Lancet Oncol 2002;3:145-53.
28. National Comprehensive Cancer Network. Clinical practice guidelines in oncology v.2.2004, cancer and treatment related anemia. http://www.nccn.org/professionals/physician_gls/. Accessed 23 November 2004.
29. Stasi R, Abriani L, Beccaglia P, Terzoli E, Amadori S. Cancer-related fatigue: evolving concepts in evaluation and treatment. Cancer 2003;98:1786-801.
30. Volgezang NJ, Breitbart W, Cella D, Curt GA, Groopman GE, Horning SJ. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. Haematology 1997;34(Suppl 3):4-12.
31. Cella D, Jin-shei L, Chih-Hung C, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002;94:528-38.
32. Ahlberg K, Ekman T, Gaston-Johansson F, Mock V. Assessment and management of cancer-related fatigue in adults. Lancet 2003; 362:640-50.
33. Tchekmedyian NS. Anemia in cancer patients: significance, epidemiology, and current therapy. Oncology (Huntingt) 2002; 16(9 Suppl 10):17-24.
34. Barrett-Lee PJ, Bailey NP, O'Brien ME, Wager E. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 2000;82:93-7.
35. Caro JJ, Salas M, Ward A, Gross G. Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer 2001;91:2214-21.
36. Harrison LB, Shasha D, Homel P. Prevalence of anemia in cancer patients undergoing radiotherapy: prognostic significance and treatment. Oncology 2002;63 (Suppl 2):11-18.
37. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40:2293-306
38. Gleeson C, Spencer D. Blood transfusion and its benefits in palliative care. Palliat Med 1995;9:307-13.
39. Mohandas K, Aledort L. Transfusion requirements, risks, and costs for patients with malignancy. Transfusion 1995;35:427-30.
40. Ortega A, Dranitsaris G, Puodziunias A. A clinical and economic evaluation of red blood cell transfusions in patients receiving cancer chemotherapy. Int J Technol Assess Health Care 1998; 14:788-98.
41. National Institute for Clinical Excellence. Improving outcomes in haemato-oncology cancer. London: NICE; 2003. URL: www.nice.org.uk. Accessed 20 September 2004.
42. Ortho Biotec Website. URL: http://www.orthobiotech.co.uk/IOB/ getFile?file=/Internet_UK/00._Miscellaneous/Eprex_SmPC_UK_July_2003.pdf. Accessed 24 June 2004.
43. Roche website. URL: www.rocheuk.com/ProductDB/Documents/rx/spc/ NeoRecormon_PFS_SPC.pdf. Accessed 24 June 2004.
44. EMEA website. URL: www.emea.eu.int/humandocs/PDFs/EPAR/Neorecormon/ 091096en4.pdf. Accessed 24 June 2004.
45. AMGEN website. URL: www.aranesp.com/patient/anemia_chemo/treatment/ index.jsp. Accessed 24 June 2004.
46. National Institute for Clinical Excellence. NICE final scope. URL:www.nice.org.uk. Accessed 15 September 2004.
47. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy related anaemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004; 22: 1301-7.
48. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, et al. Erythropoietin for patients with malignant disease. In The Cochrane Library (Issue 3) Oxford: updated Software; 2004.
49. Blue Cross & Blue Shield Association Evidence-based Practice Center. Uses of erythropoietin for anemia in oncology. Evidence Report/ Technology Assessment No. 30. Agency for Healthcare Research and Quality 2001;30.
50. Glaspy J, Bukowski RM, Steinberg D. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15:1218-34.
51. Demetri G, Kris M, Wade J. Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998;16:3412-25.
52. Gabrilove JL, Cleeland CS, Livingstone RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19:2875-82.
53. Neymark N. Assessment of the economic value of epoetin use in anemic cancer patients. Expert Review of Pharmacoeconomics and Outcomes Research 2002;1:167-75.
54. Cella D. The effects of anaemia and anaemia treatment on the quality of life of people with cancer. Oncology 2002;16: 125-32.
55. Demetri G. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer 2001;84:31-7.
56. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:2201-16.
57. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennet CL, Cella D. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines for the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20:4083-107.
58. Ludwig H, Fritz. E. Anaemia in cancer patients: patient selection and patient stratification in epoetin treatment. Semin Oncol 1998; 25:35-8.
59. Adam JR, Elting LS, Lyman GH, George JN, Lembersky BC, Armitage JO. Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries. Am J Med 2004;116:28-34.
60. Cavill I. Reducing blood transfusion. Focus should be on improving patients' ability to make own blood. BMJ 2002;325:655.
61. Bosanquet N, Tolley K. Treatment of anaemia in cancer patients: implications for supportive care in the National Health Service Cancer Plan. Curr Med Res Opin 2003;19:643-50.
62. Hyde C, Wilson J, Bayliss S, Bohlius J, Brunskill S, Craddock M. Protocol - the effectiveness and cost-effectiveness of epoetin alfa & beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. URL: www.nice.org.uk/pdf/ Final_Protocol_anaemia.pdf. Accessed 25 February 2005.
63. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19:2865-74.
64. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-20.
65. Coiffier B, Boogaerts M, Kaine C. Impact of epoetin beta versus standard care on quality of life in patients with malignant disease, 6th Congress of the European Haematological Association; 2001. Abstract 194.
66. Arslan M, Kurt E, Evrensel T, Gonullu G, Demiray M, Kanat O, et al. Efficacy of different usage strategies of recombinant human erythropoietin (rHuEPO) in platinum containing chemotherapy. Proc Am Soc Clin Oncol 21:2002 (abstr 2884).
67. Razzouk BI, Hockenberry M, Hinds PS, Feusner J, Rackoff W, Hord JD. Influence of hemoglobin response to Epoetin alfa on quality of life in anemic children with cancer receiving myelosuppressive chemotherapy [abstract]. ASH 2004; Abstract 8527.
68. Beggs VL, Disalvo WM, Meyer LP, Dragnev KH, Gibson JJ, Hoopes PJ, et al. Fatigue and plasma cytokines in a randomized double-blind placebo-controlled trial of epoetin alfa in patients undergoing combined modality therapy for unresectable non-small cell lung cancer (NSCLC) [abstract]. ASCO 2003; Abstract 2948.
69. Bindi M, Montemaggi P, Sabatino M, Paolelli R, Petrioli R, Morelli R, et al. Reticulocytes can represent an early indicator of the erythropoietic response to Darbepoetin alfa in the anaemia by chemotherapy [abstract]. ASCO 2004; Abstract 8245.
70. Blayney D, Fesen M, Mirtsching BC, Katz D, Tomita D, Colowick A. Every 2 week darbepoetin alfa improves hemoglobin in anemic patients with cancer undergoing chemotherapy: a stratified, analysis by tumor type [abstract]. ASH 2003; Abstract 3779.
71. Blohmer JU, Wurschmidt F, Petry U, Weise G, Sehouli J, Kimmig R. 6th interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study: sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for patients with high-risk cervical cancer [abstract]. ASCO 2003; Abstracts 1798.
72. Chang J, Couture F. Once weekly epoetin alfa maintains hemoglobin, improves quality of life and reduces transfusion in breast cancer patients receiving chemotherapy [abstract]. ASCO 2002; Abstract 1816.
73. Charu V, Belani CP, Gill AN, Bhatt M, Ben Jacob A, Tomita D, et al. Every-2-week (Q2W) dosing of darbepoetin alfa in patients with anemia of cancer (AOC): interim analysis of a randomized, controlled study. Blood 2003;102:1816.
74. Crawford J, Rober F, Perry M, Belani CP, Sarokhan B. Epoetin alfa 40,000 u once weekly maintains hemoglobin in advanced non-small-cell lung cancer patients receiving first-line chemotherapy [abstract]. ASCO 2003; Abstract 2527.
75. Famoyin C, Byrnes C, Roberts S, Gollob J, Atkins M, Mier J, et al. A randomized phase II study of thalidomide with or without erythropoietin (EPO) in metastatic renal cell carcinoma (RCC) [abstract]. ASCO 2004; Abstract 4747.
76. Glaspy J, Tchekmedyian NS, Gupta S. Darbepoetin alfa is cost effective compared to epoetin alfa for treatment of anemia in cancer patients receiving chemotherapy [abstract]. ASH 2002; Abstract 3447.
77. Henze G, Michon J, Morland B, Perek D, Rizzari C, Zoubek A. Phase III randomized study: efficacy of epoetin alfa in reducing blood transfusions in newly diagnosed pediatric cancer patients receiving chemotherapy [abstract]. ASCO 2002; Abstract 1547.
78. Janinis D, Dafni U, Aravantinos G, Kalofonos HP, Papakostas D, Tsavdaridis D, et al. Quality of life (QoL) outcome of epoetin alfa (EPO-A) in anemic cancer patients undergoing platinum or non-platinum-based chemotherapy: a randomized study conducted by the Hellenic Cooperative Oncology Group [abstract]. Proc Am Soc Clin Oncol 2003;22:789.
79. Kotasek D, Albertsson M, Mackey J. Randomized, double-blind, placebo-controlled, dose-finding study of darbepoetin alfa administered once every 3(Q3W) or 4(Q4W) weeks in patients with solid tumors [abstract]. ASCO 2002; Abstract 1421.
80. Marinaccio M, Mele E, Giota F, Cantinieri C, Cocca M, Policlinico B. Pretreatment normalization of mild anemia with epoetin alfa: impact on the outcome in epithelial ovarian cancer patients [abstract]. ASCO 2003; Abstract 1952.
81. O'Shaughnessy J, Vukelja S, Savin M, Holmes FA, Jones M, Royall D, et al. Effects of epoetin alfa (Procrit) on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy: a double blind, randomized, placebo-controlled trial [abstract]. ASCO 2002; Abstract 1449.
82. Recasens V, Rubio-Martinex A, Gomez-Barrera M, Rubio-Felix D, Giralt M. A pharmacoeconomical analysis comparing epoetin alpha vs transfusion in patients with anemia associated to multiple myeloma [abstract]. ASH 2003; Abstract 1801.
83. Savonije J, Van Groeningen C, Van Bochove A, Pinedo H, Giaccone G. Early intervention with epoetin-alfa during platinum-based chemotherapy [abstract]. ASCO 2004; Abstract 8111.
84. Silberstein PT, Witzig TE, Sloan JA, Mailliard JA, Rowland KM, Krook JE, et al. Weekly erythropoietin for patients with chemotherapy induced anemia: a randomized, placebo-controlled trial in North Central Cancer Treatment Group [abstract]. ASCO 2002; Abstract 1422.
85. Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, et al. Phase III, randomized, double-blind study of epoetin alfa versus placebo in anemic patients with cancer undergoing chemotherapy. J Clin Oncol 2004; 23:2606-17.
86. Smith RE, Tchekmedyian NS, Richards D, Klarnet J, Fleishman A. Darbepoetin alfa effectively alleviates anemia in patients with chronic anemia of cancer: efficacy and pharmacokinetic results of a dose-escalation study [abstract]. ASCO 2002; Abstract 1465.
87. Straus DJ, Turner RR, Testa MA, Hayes JF, Sarokhan BJ. Epoetin alfa treatment improves quality of life and increases hemoglobin levels during chemotherapy for lymphoma, chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) patients with mild to moderate anemia [abstract]. ASH 2002; Abstract 828.
88. Vadhan-Raj S, Skibber JM, Crane C, Bueso-Ramos CE, Rodriquez-Bigas MA, Feig BW, et al. Randomized, double-blind, placebo-controlled trial of Epoetin Alfa (Procrit) in patients with rectal and gastric cancer undergoing chemo-radiotherapy (CT/RT) followed by surgery: early termination of the trial due to increased incidence of thromboembolic events (TEE) [abstract]. Blood (ASH Annual Meeting Abstracts) 2004;104:Abstract 2915.
89. Sloan JA, Witzig TE, Silberstein PT, Novotny PJ, Allred JB, Baker BA, et al. Quality of life, blood transfusions, and toxicity, in anemic patients with advanced cancer receiving weekly erythropoietin while on chemotherapy: results from a phase III randomized double blind placebo controlled study [abstract] ASH 2002; Abstract 1103.
90. Kotasek D, Steger G, Faught W, Underhill C, Poulsen E, Colowick AB, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003;39:2026-34.
91. Smith RE. A dose and schedule finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer 2003; 88:1851-8.
92. Oncology Drugs Advisory Committee, Luksenburg H, Weir A, Wager R. Safety concerns associated with Aranesp (darbepoetin alfa), Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the treatment of anemia associated with cancer chemotherapy. 2004, http://www.fda.gov/ohrms/ dockets/ac/04/briefing/40378B2_04_FDA-Aranesp-Procrit.doc. Accessed 4 February 2005.
93. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993;29A Suppl 2:S2-8.
94. Carabantes FJ, Benavides M, Trujillo R, Cobo M, Hebrero ML, Garcia S. Epoetin alfa in the prevention of anemia in cancer patients undergoing platinum-based chemotherapy (CT). A prospective randomized study [abstract]. ASCO 1999; Abstract 2303.
95. Cascinu S, Fedeli A, Del Ferro E, Luzi FS, Catalano G. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 1994; 12:1058-62.
96. Case DC Jr, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993; 85:801-6.
97. Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995; 86:4446-53.
98. Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001; 113:172-9.
99. Del Mastro L, Venturini M, Lionetto R, Garrone O, Melioli G, Pasquetti W, et al. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 1997;15:2715-21.
100. Dunphy FR, Harrison BR, Dunleavy TL, Rodriguez JJ, Hilton JG, Boyd JH. Erythropoietin reduces anemia and transfusions: a randomized trial with or without erythropoietin during chemotherapy. Cancer 1999; 86:1362-7.
101. Henke M, Guttenberger R, Barke A, Pajonk F, Potter R, Frommhold H. Erythropoietin for patients undergoing radiotherapy: a pilot study. Radiother Oncol 1999;50:185-90.
102. Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol 1994;21(2 Suppl 3):21-8.
103. Italian Cooperative Study Group for Rhuepo in Myelodysplastic Syndromes. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 1998;105:1070-4.
104. Kunikane H, Watanabe K, Fukuoka M, Saijo N, Furuse K, Ikegami H, et al. Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer. Int J Clin Oncol 2001; 6:296-301.
105. Kurz C, Marth C, Windbichler G, Lahousen M, Medl M, Vavra. N. et al. Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study. Gynecol Oncol 1997; 65:461-6.
106. Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 1998;9:255-60.
107. Österborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, et al, European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. Blood 1996;87:2675-82.
108. österborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, Epoetin Beta, in hematologic malignancies. J Clin Oncol 2002;20:2486-94.
109. Quirt I, Micucci S, Moran LA, Pater J, Browman G. The role of recombinant human erythropoietin (EPO) in reducing red blood cell transfusions and maintaining quality of life (QoL) in patients with lymphoma and solid tumours receiving cytotoxic chemotherapy. Results of a randomized, double-blind, placebo-controlled clinical trial. Blood 1996;88(10 Suppl 1):347a.
110. Rose E, Rai K, Revicki D, et al. Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO). Blood 1994;84(10 Suppl):526a.
111. Silvestris F, Romito A, Fanelli P, Vacca A, Dammacco F. Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Ann Hematol 1995;70:313-18.
112. Ten Bokkel Huinink WW, de Swart CA, van Toorn DW, Morack G, Breed WP, Hillen HF, et al. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 1998;15:174-82.
113. Thatcher N, De Campos ES, Bell DR, Steward WP, Varghese G, Morant R, et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 1999; 80:396-402.
114. Thompson JA, Gilliland DG, Prchal JT, Bennett JM, Larholt K, Nelson RA, et al. GM/EPO MDS Study Group. Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. Blood 2000;95:1175-9.
115. Throuvalas N, Antonadou D, Boufi M, Lavey R, Malamos N. Erythropoietin decreases transfusion requirements during radiochemotherapy [abstract]. ASCO Annual Meeting 2000; Abstract 1558.
116. Welch RS, James RD, Wilkinson PM, FB. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer. Cancer J Sci Am 1995;1:261.
117. Wurnig C, Windhager R, Schwameis E, Kotz R, Zoubek A, Stockenhuber F, et al. Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study). Transfusion 1996; 36:155-9.
118. Leyland-Jones B, BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4:459-60.
119. Aravantinos G, Linardou H, Makridaki D, Laiou E, Zafiropoulos A, Janninis J, et al. Recombinant human erythropoietin for platinum-based chemotherapy-induced anaemia: a single-centre randomised study. Journal of Balkan Union of Ontology 2003;8:127-32.
120. Bamias A, Aravantinos G, Kalofonos C, Timotheadou N, Siafaka V, Vlahou I, et al. Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (Rhuepo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology 2003; 64:102-10.
121. Casadevall N, Durieux R Dubois S, Hemery F, Lepage E, Quarre MC, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004; 104:321-7.
122. Hedenus M, Hansen S, Taylor K, Arthur C, Emmerich B, Dewey C, et al. Randomized, dosefinding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 2002;119:79-86.
123. Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003; 122:394-403.
124. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
125. Huddart RA, Welch RS, Chan S, Perren T, Atkinson R. A prospective randomised comparative-group evaluation of epoetin alfa for the treatment of anaemia in UK cancer patients receiving platinum-based chemotherapy. Ann Oncol 2002;13:177.
126. Iconomou G, Koutras A, Rigopoulos A, Vagenakis AG, Kalofonos HP. Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: results of a randomized, controlled trial. J Pain Symptom Manage 2003;25:512-18.
127. Rosen FR, Haraf DJ, Kies MS, Stenson K, Portugal L, List MA, et al. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res 2003;9:1689-97.
128. Rosenzweig MQ, Bender CM, Lucke JP, Yasko JM, Brufsky AM. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage 2004;27:185-90.
129. Sweeney PJ, Nicolae D, Ignacio L, Chen L, Roach M, III, Wara W et al. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final-report of a randomized, open-labelled, phase II trial. Br J Cancer 1998; 77:1996-:2002.
130. Thomas H, McAdam KF, Thomas RJ, Joffe JK, Sugden EM, Awwad ST, et al. Early intervention with Epoetin alfa for treatment of anaemia and improvement of quality of life in cancer patients undergoing myelotoxic chemotherapy. Ann Oncol 2002;13:177.
131. Boogaerts M, Coiffier B, Kainz C. Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer 2003; 88:988-95.
132. World Health Organization. WHO handbook for reporting results of cancer treatment. WHO offset publication 48. Geneva: WHO; 1979.
133. Parmar M, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-34.
134. Deeks JJ, Dinnes J, Amico R, Sowden AJ, Sakarovitch C, Song F. Evaluating non-randomised intervention studies. Health Technol Assess 2003;7:27.
135. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001; 285:437-43.
136. Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004;351:1403-8.
137. Jones M, Schenkel B, Just J, Fallowfield L. Epoetin alfa improves quality of life in patients with cancer. Results of a meta-analysis. Cancer 2004;101:1721-32.
138. Ross SD, Fahrbach K, Frame D, Scheye R, Connelly JE, Glaspy J. The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review. Clin Ther 2003;25:1786-805.
139. Seidenfeld J, Piper M, Flamm C, Hasselblad V, Armitage JO, Bennett CL, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001;93:1204-14.
140. Fallowfield L, Gagnon D, Zagari M, Cella D, Bresnahan B, Littlewood TJ, et al. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer 2002;87:1341-53.
141. Fairclough DL, Gagnon DD, Zagari MJ, Marschner N, Dicato M, Epoetin Alfa Study Group. Evaluation of quality of life in a clinical trial with
142. Henry DH, Brooks BJ Jr, Case DC Jr., Fishkin E, Jacobson R, Keller AM, et al. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am 1995; 1:252.
143. Tchekmedyian NS, Kallich J, McDermott A, Fayers P, Erder MH. The relationship between psychologic distress and cancer-related fatigue. Cancer 2003;98:198-203.
144. Cella D, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 2003;14:511-19.
145. Drummond MF, O'Brien JB, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes, 2nd ed. Oxford: Oxford University Press; 1997.
146. Barosi G, Marchetti M, Liberato NL. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 1998;78:781-7.
147. Cremieux PY, Finkelstein SN, Berudt ER, Crawford J, Slavin MB. Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia. Pharmacoeconomics 1999;16:459-72.
148. Martin SC, Gagnon DD, Zhang L, Bokemeyer C, Van Marwijk KM, van Hout B. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer. Pharmacoeconomics 2003;21:1153-69.
149. Ortega A, Dranitsaris G, Puodziunas AL. What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis. Cancer 1998;83:2588-96.
150. Sheffield R, Sullivan SD, Saltiel E, Nishimura L. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 1997; 31:15-22.
151. Abels RI, Larhot KM, Krantz KD, Bryant EC. Recombinant human erythropoietin (r-FuEPO) for the treatment of anemia of cancer. In Murphy MJ Jr, editor. Blood cell growth factors; their present and future use in hematology and oncology. Proceedings of the Beijing Symposium. Ohio: Alpha Med Press, 1991. pp. 121-41.
152. Brown RE, Hutton J, Burrell A. Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics 2001; 19(11):1091-102.
153. Turner R, Anglin P, Burkes R, Couture F, Evans W, Goss G, et al., Canadian Cancer and Anemia Guidelines Development Group. Epoetin alfa in cancer patients: evidence-based guidelines. J Pain Symptom Manage 2001;22(5):954-65.
154. Aapro M, Bajetta E, Freund M, Littlewood TJ, Nortier JWR, Rapoport B. Is there a possible survival benefit to increasing hemoglobin levels with epoetin alfa during chemotherapy? Eur J Cancer Suppl 1990 2004; 2:20-8.
155. Littlewood TJ. Efficacy and quality of life outcomes of epoetin-alpha in a double-blind, placebo-controlled, multicentre study of cancer patients receiving non-platinum-containing chemotherapy. Proceedings of the Annual San Francisco Cancer Symposium 2002;37:34-7.
156. Littlewood TJ. Efficacy and quality of life outcomes of epoetin-alpha in a double-blind, placebo-controlled, multicentre study of cancer patients receiving non-platinum-containing chemotherapy. Front Radiat Ther Oncol 2002;37:34-7.
157. Littlewood TJ, Nortier J, Rapoport B, Pawlicki M, de Wasch G, Vercamman E, et al. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy. Hematol Oncol 2003;21:169-80.
158. Pirker R, Vansteenkiste J, Gateley J, Yates P, Colowick A, Musil J. A phase III, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum-treatment for lung cancer. Eur J Cancer 2002; 38:449.
159. Kallich JD, Tchekmedyian NS, Damiano AM, Shi J, Black JT, Erder MH. Psychological outcomes associated with anemia-related fatigue in cancer patients. Oncology (Huntingt) 2002;16(9 Suppl 10):117-24.
160. Vansteenkiste J, Poulsen E, Rossi G, Glaspy J. Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations. Oncology (Huntingdon) 2002;16:45-55.
161. FACT website. URL: www.facit.org. Accessed 6 December 2004.
162. Bowling A. Measuring disease: a review of disease specific quality of life measurement scales. Buckingham: Oxford University Press; 2001.
163. McDowell I, Neymark N. Measuring health: a guide to rating scales and questionnaires. Buckingham: Oxford University Press; 1996.
164. Bowling A. Measuring health: a review of quality of life measurement scales. Buckingham: Oxford University Press; 1997.
165. Derogatis L. Brief Symptom Inventory (BSI). 1975. URL: www.iprc.unc.edu/ longscan/Measures%20Manual/Ages5to11/m3.pdf. Accessed 06 December 2004.
166. Fayers P, Mackey J. Quality of life assessment, analysis and interpretation. London: John Wiley and Sons; 2000.
167. 2004. Patient Reported Outcome and Quality of Life Instruments Database. URL: www.qolid.org. Accessed 6 December 2004.
168. Morasso G, Costantini M, Baracco G, Borreani C, Capelli M. Assessing Psychological Distress in cancer patients: validation of a self-administered questionnaire. Oncology 1996;53:295-302.
169. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center; 1993.
170. Song FJ, Fry-Smith A, Davenport C, Bayliss S, Adi Y, Wilson JS, et al. Identification and assessment of ongoing trials in health technology assessment reviews. Health Technol Assess 2004; 8(44).
171. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, et al. Erythropoietin for patients with malignant disease. Cochrane Library Issue 3. 2004.